Relypsa Inc. (RLYP) Given Average Recommendation of “Hold” by Analysts
Relypsa Inc. (NASDAQ:RLYP) has earned an average rating of “Hold” from the seventeen analysts that are covering the firm. Twelve equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $36.76.
RLYP has been the subject of a number of recent research reports. Vetr lowered shares of Relypsa from a “strong-buy” rating to a “buy” rating and set a $21.68 price target for the company. in a research note on Monday, June 13th. BTIG Research restated a “buy” rating and set a $35.00 price target on shares of Relypsa in a research note on Wednesday, June 29th. Morgan Stanley restated an “underweight” rating and set a $9.00 price target on shares of Relypsa in a research note on Tuesday, July 12th. Cantor Fitzgerald set a $41.00 target price on shares of Relypsa and gave the stock a “buy” rating in a research note on Thursday, July 21st. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Relypsa in a research note on Tuesday, June 28th.
In related news, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of Relypsa stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $32.00, for a total value of $129,395,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder James D. Dondero sold 37,000 shares of Relypsa stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $31.96, for a total value of $1,182,520.00. The disclosure for this sale can be found here.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/relypsa-inc-rlyp-given-average-recommendation-of-hold-by-analysts.html
Large investors have recently added to or reduced their stakes in the company. Royce & Associates LP increased its stake in Relypsa by 14.7% in the first quarter. Royce & Associates LP now owns 467,700 shares of the company’s stock valued at $6,337,000 after buying an additional 60,000 shares during the last quarter. Deerfield Management Co. boosted its position in Relypsa by 108.1% in the first quarter. Deerfield Management Co. now owns 1,873,471 shares of the company’s stock worth $25,386,000 after buying an additional 973,190 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Relypsa by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 378,047 shares of the company’s stock worth $5,123,000 after buying an additional 4,419 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in Relypsa by 20.3% in the first quarter. UBS Asset Management Americas Inc. now owns 515,790 shares of the company’s stock worth $6,989,000 after buying an additional 86,890 shares during the last quarter. Finally, Scopia Capital Management LP bought a new position in Relypsa during the first quarter worth $4,930,000.
Shares of Relypsa (NASDAQ:RLYP) remained flat at $31.99 on Tuesday. The firm’s 50 day moving average is $30.31 and its 200 day moving average is $20.28. Relypsa has a 52-week low of $10.26 and a 52-week high of $32.12.
Relypsa (NASDAQ:RLYP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.87) earnings per share for the quarter, missing the consensus estimate of ($1.56) by $0.31. The firm had revenue of $5.22 million for the quarter, compared to the consensus estimate of $5.45 million. On average, equities research analysts predict that Relypsa will post ($6.33) earnings per share for the current fiscal year.
Relypsa Company Profile
Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.
Receive News & Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related companies with MarketBeat.com's FREE daily email newsletter.